Tiger Balm marketer earns FDA warning
This article was originally published in The Tan Sheet
Executive SummarySingapore-based Haw Par Healthcare's Tiger Balm Pain Relieving Patch is a misbranded drug because it makes drug claims such as "stimulating blood circulation" and thus cannot be marketed as an OTC, FDA says. Further, the agency found "significant" violations of good manufacturing practices - including failure to set appropriate specifications - during an inspection of Haw Par's facility, FDA said in a July 20 warning letter
You may also be interested in...
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Compliance Corner: The 10 Best – And 10 Worst – Things You Can Do When FDA Inspects Your Firm (Part 10)
A panel of longtime industry experts offer manufacturers a list of things they should and shouldn’t do when an investigator from the US agency knocks on their facility door. In this tenth and final installment of a 10-part series, the experts explain why it’s important to be honest with investigators at all times.
It hasn’t even happened yet, but Brexit has already had a huge impact on the EU regulatory network and on the life science sector operating in the EU, particularly in the UK. We look back at some of the key events over the past ten years that have woven the UK ever more closely into the EU’s tight-knit regulatory network, and why the UK’s future links with that network will remain uncertain after the country leaves the EU on 31 January.